Nicox sells ophthalmic Dx unit to Valeant; sharpens focus on therapeutics
This article was originally published in Clinica
Executive Summary
Nicox has divested its US ophthalmic diagnostics unit to Valeant Pharmaceuticals International in a deal worth up to $20m. The move will enable Nicox to focus exclusively on growing its ophthalmic therapeutics business, which has expanded in the last 12 months through four separate acquisitions.